Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

contact lenses

  • Home
  •  
  • contact lenses



  • Most Read
  • Latest Comments
  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    • News

  • As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • AFT’s pain relief medication Maxigesic gets FDA approval, but the IV version still under scrutiny
    AFT’s pain relief medication Maxigesic gets FDA approval, but the IV version still under scrutiny
    • News

  • Understanding the importance of clinical trials when investing in medical research driven biotech
    Understanding the importance of clinical trials when investing in medical research driven biotech
    • Explainers

  • FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering
    • News

    FDA relaxes clinical trial guidelines, opens U.S opportunity to Visioneering

    Medtech developer Visioneering Technologies (ASX: VTI) may soon have its NaturalVue Multifocal (NVMF) contact lenses re-classified by the FDA which has just approved the first contact lenses which slow the progression of nearsightedness.  The FDA approval was given to CooperVision’s MiSight® 1 day contact lens which slows the progression of myopia specifically in children. The

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.